Efficacy and safety of a new triple-combination agent for the treatment of facial melasma

Cutis

Volumn 72, Issue 1, 2003, Pages 67-72

  Taylor, Susan C ^a   Torok, Helen ^b   Jones, Terry ^c   Lowe, Nicholas ^d   Rich, Phoebe ^e   Tschen, Eduardo ^f   Menter, Alan ^g   Baumann, Leslie ⁿ   Wieder, Joshua J ^h   Jarratt, Michael M ⁱ   Pariser, David ^j   Martin, Dale ^k   Weiss, Jonathan ^l   Shavin, Joel ^l   Ramirez, Nini ^m  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b HMT Dermatology Associates Inc   (United States)

^c J and S Studies   (United States)

^d SAINT JOHN'S HEALTH CENTER   (United States)

^e Northwest Cutaneous Research Specialists   (United States)

^f Academic Dermatology Associates   (United States)

^g Texas Dermatology Associates PA   (United States)

^h Private Practice   (United States)

ⁱ DermResearch Inc   (United States)

^j EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^k Skin Surgery Medical Group   (United States)

^l Gwinnett Clinical Research Center   (United States)

^m Hill Dermaceuticals Inc   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; FLUOCINOLONE ACETONIDE; HYDROQUINONE; RETINOIC ACID;

ADULT; AGED; ARTICLE; CHLOASMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DESQUAMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRY SKIN; ERYTHEMA; FACE MALFORMATION; FEMALE; HUMAN; HYDROPHILICITY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN; SKIN ABRASION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN PIGMENTATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FACIAL DERMATOSES; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; HUMANS; HYDROQUINONES; MELANOSIS; MIDDLE AGED; OINTMENTS; PROBABILITY; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRETINOIN;

EID: 0141993673     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
2. Mosher DB, Fitzpatrick TB, Ortonne J-P, et al. Hypomelanoses and hypermelanoses. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. Vol 1. New York, NY: McGraw-Hill; 1999:945-1017.
3. Barankin B, Silver SG, Carruthera A. The skin in pregnancy. J Cut Med Surg. 2002;6:236-240.
4. Sober AF, Fitzpatrick TB. Disturbances of pigmentation. section I. mechanisms of pigmentation in man. In: Moschella SL, Pillsbury DM, Hurley HJ Jr, eds. Dermatology. Vol 2. Philadelphia, Pa: WB Saunders Co; 1975:1085.
5. Vasquez M, Maldonado H, Benmaman C, et al. Melasma in men. Int J Dermatol. 1988;27:25-27.
6. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894-899.
7. Giannotti B, Melli MC. Current approaches to the treatment of melasma. Clin Drug Invest. 1995;10(suppl 2):57-64.
8. Griffiths CEM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma, a vehicle-controlled, clinical trial. Br J Dermatol. 1993;129:415-421.
9. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol. 1989;143(suppl):58-61.
10. Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982;20:55-58.
11. Kimbrough-Green CK, Griffiths CEM, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727-733.
12. Gano SE, Garcia RL. Topical tretinoin, hydroquinone, and betamethasone valerate in the therapy of melasma. Cutis. 1979;23:239-241.
13. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol. 1998;25:587-596.
14. Katsambas A, Antoniou CH. Melasma: classification and treatment. J Eur Acad Dermatol Venereol. 1995;4:217-223.
15. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
16. Kligman LH, Schwartz E, Lesnik RH, et al. Topical tretinoin prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect. Curr Probl Dermatol. 1993;21:79-88.
17. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996;135:60-64.
18. Sanchez PN, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698-710.
19. Denton CR, Lerner AB, Fitzpatrick TB. Inhibition of melanin formation by chemical agents. J Invest Dermatol. 1952;18:119-135.
20. Jimbow K, Obata H, Pathak MA, et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62:436-449.
21. Penney KB, Smith CJ, Allen JC, et al. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes. J Invest Dermatol. 1984;82:308-310.
22. Craven NM, Griffiths CE. Topical retinoids and cutaneous biology. Clin Exp Dermatol. 1996;21:1-10.